PDS Biotechnology
PDSB
30 hedge funds and large institutions have $6.92M invested in PDS Biotechnology in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 8 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
0.67% less ownership
Funds ownership: 14.82% → 14.14% (-0.67%)
3% less funds holding
Funds holding: 31 → 30 (-1)
10% less capital invested
Capital invested by funds: $7.68M → $6.92M (-$759K)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$285K |
| 2 |
MWM
Minot Wealth Management
Westwood,
Massachusetts
|
+$108K |
| 3 |
Renaissance Technologies
New York
|
+$98.3K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$77.9K |
| 5 |
Goldman Sachs
New York
|
+$42.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$978K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$47K |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$44K |
| 4 |
AFM
Andesa Financial Management
Allentown,
Pennsylvania
|
-$36.5K |
| 5 |
VF
Virtu Financial
New York
|
-$24K |
PDSB Hedge Fund Activity: Q4 2020 in Review
30 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q4 2020, worth a combined $6.92M — down 9.9% from $7.68M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of PDSB and 7 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $285K. The largest seller was Sabby Management, exiting entirely with an estimated $978K sold.
- 30 institutional investors held PDS Biotechnology (PDSB) as of Q4 2020, down from 31 in Q3 2020.
- Funds reported $6.92M of PDS Biotechnology stock for Q4 2020, down 9.9% quarter-over-quarter.
- 7 funds opened new PDS Biotechnology positions in Q4 2020 and 8 closed out, a net change of -1 holder.
- The largest PDS Biotechnology buyer in Q4 2020 was Vanguard Group, an estimated $285K added.
- The largest PDS Biotechnology seller in Q4 2020 was Sabby Management, an estimated $978K sold.
Based on aggregated 13F filings for Q4 2020.